Of importance in its use for ocular indications, mapracorat increases IOP in rabbits to a lower extent than dexamethasone and increases the expression of myocilin, a protein thought to be involved in the progression of glaucoma, to a significantly lesser extent than classic steroids [25,26]. This evidence concerns the gene MYOC and glaucoma.